ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
83,295
0,64%
Bitcoin
63 734,41
-0,25%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Keros Therapeutics Inc (KROS)

  7. Keros Therapeutics Inc (KROS) Actualités

KROS Keros Therapeutics Inc

60,57
3,47 (6,08%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Keros Therapeutics Inc KROS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
3,47 6,08% 60,57 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
57,32 57,32 62,19 60,57 57,10
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/3/202413:00GLOBEKeros Therapeutics Announces U.S. FDA Fast Track Designation..
06/3/202414:01EDGAR2Form 8-K - Current report
05/3/202414:02EDGAR2Form 8-K - Current report
05/3/202414:01EDGAR2Form 8-K - Current report
05/3/202414:00GLOBEKeros Therapeutics to Present at Leerink Partners 2024..
28/2/202422:02EDGAR2Form 8-K - Current report
28/2/202422:01GLOBEKeros Therapeutics Reports Recent Business Highlights and..
23/2/202423:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202402:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202402:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202414:00GLOBEKeros Therapeutics To Present at Pulmonary Vascular Research..
09/1/202414:01EDGAR2Form 8-K - Current report
09/1/202414:00GLOBEKeros Therapeutics Announces Closing of Upsized Public..
08/1/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:04EDGAR2Form 8-K - Current report
04/1/202422:04EDGAR2Form 144 - Report of proposed sale of securities
04/1/202422:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/1/202403:29GLOBEKeros Therapeutics Announces Pricing of Upsized Public..
03/1/202422:05GLOBEKeros Therapeutics Announces Proposed Public Offering of..
03/1/202422:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/1/202414:04EDGAR2Form 8-K - Current report
11/12/202312:02EDGAR2Form 8-K - Current report
11/12/202312:00GLOBEKeros Therapeutics Presents Clinical Data from its KER-050..
07/11/202314:01EDGAR2Form 8-K - Current report
07/11/202314:00GLOBEKeros Therapeutics to Present at Upcoming Healthcare..
06/11/202314:11EDGAR2Form 8-K - Current report
06/11/202314:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202314:01EDGAR2Form 8-K - Current report
06/11/202314:00GLOBEKeros Therapeutics Reports Recent Business Highlights and..
02/11/202314:00GLOBEKeros Therapeutics to Present at the 65th American Society..
04/10/202314:01EDGAR2Form 8-K - Current report
04/10/202314:00GLOBEKeros Therapeutics Presents Preclinical Data from its..
05/9/202314:02EDGAR2Form 8-K - Current report
05/9/202314:00GLOBEKeros Therapeutics to Present at Upcoming Healthcare..
07/8/202322:02EDGAR2Form 8-K - Current report
07/8/202314:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202314:00EDGAR2Form 8-K - Current report
07/8/202314:00GLOBEKeros Therapeutics Reports Recent Business Highlights and..
27/7/202322:01GLOBECorrected: Keros Therapeutics to Host Conference Call and..
24/7/202314:01EDGAR2Form 8-K - Current report
24/7/202314:00GLOBEKeros Therapeutics to Host Conference Call and Webcast to..
12/6/202314:00GLOBEKeros Therapeutics Announces Update to Participation at the..
09/6/202312:00GLOBEKeros Therapeutics Presents Clinical Trial and Preclinical..
07/6/202314:00GLOBEKeros Therapeutics to Present at Goldman Sach’s 44th Annual..
22/5/202315:00GLOBEKeros Therapeutics Presents Preclinical and Clinical Data..
11/5/202322:01GLOBEKeros Therapeutics to Present at the 28th Annual Congress of..

Dernières Valeurs Consultées

NASDAQ
KROS
Keros Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés